Following our deep dive into Lipoprotein(a), Dr. Ravi Kumar answers the most pressing listener questions to help you navigate the complexities of this genetic heart risk. 

In this Q&A session, we move beyond the basics to address real-world clinical concerns and the future of cardiovascular medicine.

We discuss:

• Testing the Next Generation: Why Lp(a) is essentially stable from age 5 and why testing your children can provide a 40-year head start on prevention.
• The Saturated Fat Paradox: Analyzing the Delta trials and why replacing saturated fats with carbohydrates might actually increase your Lp(a) levels.
• Exercise & The "Table" Analogy: Why exercise doesn't change the cards you’re dealt (your Lp(a) number), but fundamentally changes the "table" you're playing on.
• The Aspirin Protocol: A look at the Women's Health Study and why low-dose aspirin may specifically benefit those with the high-risk LPA gene variant.
• SiRNA Breakthroughs: An update on Pelacarsen and Olpasiran—drugs that can slash Lp(a) by 90%—and whether you should wait for them to hit the market.